In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study
Authors' conclusion
Patient's age, timing of cannulation (<4 days vs ≥4 days from intubation), and use of inotropes and vasopressors are essential factors to consider when analysing the outcomes of patients receiving ECMO for COVID-19.
Study context
- Population
- Patients aged ≥16 years receiving extracorporeal membrane oxygenation (ECMO) for refractory COVID-19 during the first wave (March 1–Sept 13, 2020), 133 centres in 21 countries
- Participants
- 1,215 patients · 133 centres
- Outcome
- In-hospital mortality and mortality 6 months after ECMO initiation
- Follow-up
- 6 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
In-hospital mortality and 6-month survival
Died in hospital
602 (50%) of 1215
Alive at 6 months among those with data
547 (95%) of 577
Observational data: associations, not effects.
Further findings
Cause of death
- Multiorgan failure leading cause of death
- 192 [36%] of 528
ECMO duration
- Median ECMO duration (IQR 8-27)
- 15 days
Return to work · 6 months
- Full-time work
- 102 (24%) of 431
- Part-time work
- 57 (13%) of 428
Rehabilitation and residual symptoms · 6 months
- Respiratory rehabilitation required
- 88 (17%) of 522
- Dyspnoea
- 185 [35%] of 523
- Cardiac symptoms
- 52 [10%] of 514
- Neurocognitive symptoms
- 66 [13%] of 512
Safety
At least one complication
- Patients with ≥1 complication
- 852 (74%)
Original publication
In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study. Lancet Respir Med. Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →